BioCentury | Nov 8, 2019
Clinical News
Roche’s RG6206 becomes second myostatin inhibitor to fail in DMD in past year
...muscular dystrophy. Roche (SIX:ROG; OTCQX:RHHBY) sent a letter Wednesday to the DMD community, including non-profit Parent Project Muscular Dystrophy...